The Quality Imperative A Commentary on the U.S. Healthcare System by Frakt, Austin B. & Carroll, Aaron E.
u
h
a
e
o
a
o
p
h
g
2
c
d
t
s
d
s
q
p
i
m
p
b
t
w
s
tThe Quality Imperative
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Austin B. Frakt, PhD, Aaron E. Carroll, MD, MSIntroduction
The U.S. healthcare system is ailing, despite thepassage of the Patient Protection and AffordableCare Act (ACA) in 2010. Although it was a mon-
mental advance, the ACA was not comprehensive
ealthcare reform, as it focused principally on expanding
ccess to health insurance. TheACA largely, althoughnot
ntirely, avoided swiftly and directly addressing two
ther problems that plague the healthcare system: high
nd rapidly increasing spending and poor population
utcomes.
Considering politics and market dynamics, neither
oses issues that are simple to solve. The $2.6 trillion U.S.
ealthcare economy involves many powerful interest
roups and major political constituencies. As the 2009–
010 health reform debate demonstrated, making major
hanges to healthcare delivery and fınancing poses fun-
amental challenges to the U.S. legislative system. Yet,
echnically, reducing growth in healthcare spending
eems paradoxically trivial: Adopt a model from any in-
ustrialized nation that has achieved lower healthcare
pending growth (Figure 1).
A more-diffıcult challenge is to increase broadly the
uality of the U.S. healthcare system, as measured by
opulation-level outcomes. In fact, a substantial problem
s that it is diffıcult to improve quality in ways that can be
easured easily. However, in some areas, quality im-
rovements can be achieved relatively easily. Adhering to
est practices and heeding the lessons of certain clinical
rials simultaneously could improve quality and reduce
aste and costs. Thus, inmany respects, we already know
ome ways to improve healthcare quality; it is imperative
hat we apply the available tools to do so.
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Domestic trends and international comparisons make
clear the fact that U.S. healthcare spending is high and
growing rapidly. Notwithstanding decades of concern
about healthcare spending; the passage of numerous
incremental reforms to public health programs (nota-
bly to Medicare and Medicaid); and various private-
sector innovations in health insurance and its provi-
sion, healthcare spending has grown from 9% of the
U.S. economy in 19801 to 18% today.2 Over that pe-
riod, growth in spending has outpaced that of other
wealthy nations, as well as overall inflation, economic
growth, and the wages of workers (Figure 1). Per-
person healthcare spending in the U.S. was about
$7500 in 2008, an extreme outlier relative to other Or-
ganisation for Economic Co-operation and Development
(OECD) nations, even accounting for the greater wealth
the U.S. enjoys.1 Federal spending on health programs
now accounts for 23% of the federal budget and is ex-
pected to grow to 34% by 2035.3 By all accounts, this
growth is unsustainable.
High healthcare spending in the U.S. might be
viewed as acceptable, or at least grudgingly tolerated, if
it resulted in consistently high-quality and broadly
enjoyed health outcomes. But it does not. Numerous
studies, examining dozens of measures of population
health, have concluded that the U.S. lags far behind its
peer nations in many measures of healthcare quality.4
Figure 2 summarizes how the U.S. compares to several
other OECD nations on various dimensions of health-
care quality: To adequately meet the needs of a diverse
population, and to receive good value in return for
expenditures, the U.S. must improve the quality of
health care delivered.
Cost-Savings the U.S. Can Implement Now
Ofcourse,we, as a country, alwayshave a choice andare free
to spendas large aproportionof theU.S. economyonhealth
care as desired.However, doing so implies some unpleasant
consequences: potential massive increases in taxation; huge
increases in debt; dramatically lower spending on other
goods and services (such as education anddefense); or some
combination thereof. In a 2010 Health Affairs article,6 Jo-
ephNewhouse, facedwith these choices, explainedwhy the
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Jtrajectory of total U.S. healthcare spending must be bent
downward. Key to his argument, however, was the observa-
tion that it is not enough to simply address healthcare
spending in federal programs, notably Medicare. The
healthcare spending problemmust be solved nationally, for
both public and private payers.
The real question, therefore, is not whether to spend
less on health care (relative to the economy or projections
of current trend) but how. Either less can be spent on
everything, or spending cuts can be targeted. The for-
mer approach risks reducing spending on necessary,
effıcient, and life-extending or life-enhancing care.
The latter approach offers an opportunity to reduce
waste and improve quality as spending is controlled.
Increasing quality and reducing waste, as spending is
tamed, sounds hard, and it is. But the U.S. already knows
where to begin and has an idea of how to do it.
Well-designed studies have shown that, often, treat-
Figure 1. Healthcare spending as a percentage of GDP in
Note: Source: OECD health data, 201029
GDP, gross domestic product; OECD, Organisation for Economic Co-operationments are offered, and paid for, that do not improve
anuary 2013outcomes. Let’s consider
just a few. About three
quarters of a million new
vertebral fractures occur in
the U.S. each year, and
people aged 50 years
have a nearly 25% chance
to have at least one such
fracture over their life-
times.7 Most such frac-
tures heal, but a substantial
number cause chronic
pain. Although surgery for
these fractures has been
controversial, the number
of vertebroplasties paid for
by Medicare nearly dou-
bled from 2001 to 2005. A
2009 study showed that
vertebroplasty for verte-
bral fractureswasnobetter
than sham (fake) surgery
in reducing pain.7 In spite
of this study,Medicare still
pays for 100,000 such pro-
cedures each year, at a cost
of $1 billion annually.8
In addition, studies
show that more than 5%
of people in the U.S. aged
30 years and more than
10% of those aged 65
years have frequent knee
pain from osteoarthritis.9
In 2009, more than
00,000 of them underwent arthroscopic surgery, at a
ost of $3 billion.10 Yet a 2002 study showed that ar-
hroscopic surgery for knee pain was no better than sham
urgery.9
An enormous list could be amassed of treatments
that have been proven to be ineffective, let alone cost
ineffective. These could include routinely using estro-
gen in menopause for chronic disease prevention,11
suppressing arrhythmias post–myocardial infarc-
tion,12 doing internal carotid artery bypasses,13 using
-blockers as fırst-line therapy to prevent stroke,14
giving estrogen to men with coronary artery disease,15
giving high-dose glucose infusions in the critical
care unit,16 using -blockers perioperatively,17 and
nappropriately using implantable cardioverter-
efıbrillators.18 Recently, theChoosingWisely campaign,
in partnership with medical provider organizations,
OECD countries
evelopment31identifıed fıve tests or procedures that are of questionable
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medical specialties (www.
abimfoundat ion.org/
Initiatives/Choosing-
Wisely.aspx).
The exact amount
spent on these proce-
dures every year is not
known, yet it is known
that they are all still com-
mon, expensive, and do
not improve outcomes at
the population level.
They provide a ready, if
politically challenging,
means to reduce spend-
ing without decreasing
quality. In fact, eliminat-
ing them would increase
quality because doing so
would avoid needless
health care, which itself
carries risk. The key is to
reform institutions and
payment systems within the broader healthcare system
that would provide incentives to eliminate them. This is
not a simple task; knowing what to do is not the same
thing as getting everyone to agree to do it.
The Way Forward
Of course it is not enough to describe areas in which
spending can be reduced without decreasing quality. A
description also must be provided of how to motivate
actors within the system—patients and providers—to
change their behavior. Two fundamentally different
views about how to do this have been offered recently.
One approach is to place the burden on patients by in-
creasing cost-sharing. Advocates of this approach, among
them current congressional Republicans, point to the
RANDHealth Insurance Experiment as support. Results of
thisprojectdo showthat individualswithhigherdeductibles
and copayments incurred lower healthcare spending.
However, that project and subsequent work have shown
that individuals are ill-equipped to differentiate between
necessary and unnecessary care.When patients cut back on
utilization, they did so indiscriminately. About half the for-
gone care would have been good for their health.19,20
The other approach, more associated with congressio-
nal Democrats and President Obama, is to focus on treat-
ment modalities that are more effective than others and
empower experts to reduce program spending on those
treatments that prove less valuable. TheAmericanRecov-
Figure 2. The quality of he
Note: Among the seven countries, 1
AUS, Australia; CAN, Canada; GER,
Co-operation and Development; UK,ery and Reinvestment Act of 2009 allocated $1.1 billion mfor comparative-effectiveness research, studies that
compare the clinical effectiveness of treatments.21 The
ACA further supports research of this type by estab-
lishing the nonprofıt Patient-Centered Outcomes Re-
search Institute.22 The fırst step in reducing wasteful
ealth spending is to identify it, which is exactly what
omparative-effectiveness research does.
The second step is to create institutional structures that
se this information to deliver care that can be justifıed on
he basis of strong evidence of effectiveness. In some
ases, such structures would expand care to improve
uality (e.g., fınancing without copayment for clinical
ervices vetted by the U.S. Preventive Services Task
orce). In other words, not all comparatively effective or
ost-effective quality improvements would necessarily be
ost-saving; they should nonetheless be pursued if they
re effective.
As noted, individuals are not always able to distinguish
etweenhelpful andunhelpful health care.However, they
eed not do so. Empowering physicians to make such
eterminations is one of the implicit goals of the ACA.
he law establishes the rules governing new accountable
are organizations (ACOs), integrated systems of provid-
rs responsible for the care of a population of patients and
t risk for the associated costs, with bonuses and penalties
ied to measured quality. ACOs can theoretically play a
ositive role in increasing quality, including through
systems of selected OECD nations
gnates the highest rank and 7 the lowest; excerpted from Davis 2010.5
any; NETH, Netherlands; NZ, New Zealand; OECD, Organisation for Economic
d Kingdomalth
desi
Germeasures that reduce wasteful spending.
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high-quality and effıcient care already exist, including
Kaiser Permanente, Group Health Cooperative of Puget
Sound, Geisinger Health System, and the Veterans
Health Administration.23,24 ACO-like concepts are being
ursued also by Blue Cross/Blue Shield of Massachu-
etts.25 Although ACOs are no panacea, and may them-
selves raise other issues, they are a reasonable start toward
encouraging the provision of higher-quality care.26
Lastly, the ACA attempts to reduce one of the high
barriers to development of a more rational, effıcient
Medicare program: politics.27 The act establishes the In-
dependent Payment Advisory Board (IPAB), which will
have the authority to make Medicare spending recom-
mendations that must be considered, without amend-
ment by Congress, under expedited procedures.28 In
brief, Congress faces a collective action problem that the
IPAB would help to address. The IPAB is severely re-
stricted by law, in terms of the range of its purview (e.g.,
until 2020 it cannot suggest changes to hospital payment
rates). Nonetheless, it is the type of body that could, one
day, streamline Medicare’s ability to implement more-
effıcient payment structures, ones that provide greater
incentives for reducing provision of care that has been
proven by research to be less effective than other
approaches.
Conclusion
The U.S. healthcare system has deeply entrenched prob-
lems relating to access, cost, and quality. These issues
have continued for decades, despite many attempts to
resolve them. If past experience is any guide, caution
should be taken in suggesting that the U.S. is now on the
right path to solving them. Even if there are clear technical
policy solutions to the problems, it is clear that politics
remains a chief barrier.
From the authors’ perspective, there is no question that
if politics and informational barriers due to proprietor-
ship were no obstacle, the system could be optimized for
cost and quality. In some sense, this type of optimization
is what the ACA is attempting to do through a politically
feasible, gradual path that seeks to minimize the political
backlash that has doomed other attempts at serious re-
form. Within the context of the structures and bodies
established by theACA, there are positive steps that could
be taken to reduce waste, improve outcomes, and de-
crease future spending.
In the U.S. today, there are medical procedures known
to do little to improve health outcomes and a lot to in-
crease costs. The U.S. should begin, right now, to con-
strain insurance coverage for such treatments. But this is
just the beginning; comparative-effectiveness research
January 2013will identify more examples. ACOs can provide incen-
tives to put that research into practice. The IPAB could be
empowered to add larger incentives toward providing
high-quality, effıcient health care.
Beyond these steps, inclusion of cost-effectiveness re-
search in reforms could be considered. It is true that this
approach would open the door to the type of decision
making seen in other national healthcare systems, such as
the National Health Service in Britain. But with scarce
public resources, does it make sense to cover treatments
with high costs that deliver relatively few quality-adjusted
life-years?
To supercharge the healthcare-system regime in this
way will require not just an unprecedented act of political
will, but unprecedented new data systems and data ac-
cess. Much about the U.S. healthcare system and its per-
formance is unknown, as it is locked up in proprietary
databases or inscrutable paper records. Moving medical
practice into the 21st century by promoting electronic
medical records systems is another goal of the ACA.
The next logical step is to tie all these goals together:
harness the data to inform comparative-effectiveness re-
search, use that research in the practice of accountable
medicine, and develop payment-system incentives to
drive the chain of innovation in quality and effıciency.
Changes such as these may sound like an impossible
dream or a Draconian nightmare. Yet, if the U.S. is going
to develop the health system those in the U.S. want, the
onemanyAmericansmistakenly think is already in place,
such incremental, quality-focused, evidence-based re-
form is not a choice. It is an imperative.
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